Cybin announces grant of u.s. patent covering proprietary deuterated psilocybin analog in its cyb003 program

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the u.s. patent and trademark office (“uspto”) has granted u.s. patent 11,724,985, to a deuterated psilocybin analog in the company's cyb003 investigational drug program. the patent, which is expected to provide exclusivi.
CYBN Ratings Summary
CYBN Quant Ranking